Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 9, 2008, Pages 912-916

  Koutroubakis, Ioannis E ^a   Sfiridaki, Aekaterini ^b   Tsiolakidou, Georgia ^a   Coucoutsi, Constantina ^a   Theodoropoulou, Angeliki ^c   Kouroumalis, Elias A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Regional Blood Bank Center   (Greece)

^c Venizelion General Hospital   (Greece)

Author keywords

Crohn's disease; Fibrinolysis; Thrombosis; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; SERPINE1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS; BLOOD;

ADULT; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE U; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 58149293739     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282faa759     Document Type: Article

References (18)

1. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007; 102:174-186.
2. Koutroubakis IE. Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2:266-272.
3. Saibeni S, Ciscato C, Vecchi M, Boscolo Anzoletti M, Kaczmarek E, Caccia S, et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006; 4:1510-1516.
4. Van Bodegraven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PC. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 1995; 30:580-585.
5. Gris JC, Schved JF, Raffanel C, Dubois A, Aguilar-Martinez P, Arnaud A, et al. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990; 63:472-475.
6. Vecchi M, Cattaneo M, de Franchis R, Mannucci PM. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 1991; 21:165-170.
7. De Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease: a study in blood plasma, colon mucosa, and faeces. Gut 1989; 30:188-194.
8. Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn's disease. Blood Coagul Fibrinolysis 1992; 3:773-778.
9. Vrij AA, Rijken J, van Wersch JW, Stockbrugger RW. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 2003; 33:75-83.
10. Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Gottl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999; 28:418-422.
11. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, et al. Assessment of thrombin activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99:1966-1970.
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 24:2-6.
13. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
14. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
15. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)-how does thrombin regulate fibrinolysis? Ann Med 2006; 38:378-388.
16. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40:431-442.
17. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83:902-905.
18. Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, et al. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol 2006; 41:318-324.